Standout Papers
- Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. (1996)
- Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase (1999)
- von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. (1998)
- Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C (1995)
- Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 (1998)
- Tumour suppression by the human von Hippel-Lindau gene product (1995)
- Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues (1997)
- The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix (1998)
- Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene (1997)
- pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation (1998)
- The Molecular Basis of Von Hippel-Lindau Disease (1997)
Citation Impact
Citing Papers
A family of structurally related RING finger proteins interacts specificallywith the ubiquitin‐conjugating enzyme UbcM41
1999
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer
2005
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth
2006
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.
2003 StandoutNobel
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma
2004
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
2005 StandoutNobel
Genetic evidence for a tumor suppressor role of HIF-2α
2005
HIF-1-Mediated Suppression of Acyl-CoA Dehydrogenases and Fatty Acid Oxidation Is Critical for Cancer Progression
2014 StandoutNobel
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases
2011 StandoutNobel
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer
2007
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene
2004 StandoutNobel
Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation
2012
Differential Regulation of the Transcriptional Activities of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) and HIF-2α in Stem Cells
2006
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
Sirtuins as regulators of metabolism and healthspan
2012 Standout
Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein
2000 StandoutNobel
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
2005 StandoutNobel
Oxygen sensors and angiogenesis
2002 StandoutNobel
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 StandoutNatureNobel
von Hippel–Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2α signaling and splenic erythropoiesis
2007
Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanisms
2007 StandoutNobel
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
2003
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
The Hypoxia-Inducible Factor 2α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo
2007 StandoutNobel
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
2011
Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34
1999
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: new perspectives
1999 StandoutNobel
HIF‐1α and HIF‐2α have divergent roles in colon cancer
2008
Comparative Sequence Analysis of the VHL Tumor Suppressor Gene
2000
NEDD8 recruits E2-ubiquitin to SCF E3 ligase
2001
The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen
2003
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
1999
Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues
2002
MUF1, A Novel Elongin BC-interacting Leucine-rich Repeat Protein That Can Assemble with Cul5 and Rbx1 to Reconstitute a Ubiquitin Ligase
2001
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
2002
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex
2001 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
RSUME, a Small RWD-Containing Protein, Enhances SUMO Conjugation and Stabilizes HIF-1α during Hypoxia
2007
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
1999
The MDM2 RING-finger domain is required to promote p53 nuclear export
2000
The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
2012
Epigenetic regulation of aging stem cells
2011
Characterization of Elongin C Functional Domains Required for Interaction with Elongin B and Activation of Elongin A
1996
Expression of Angiogenic Growth Factors in Paragangliomas
2000
Sirtuin-7 Inhibits the Activity of Hypoxia-inducible Factors
2013 StandoutNobel
Recent Insights into the Molecular Pathogenesis of Pheochromocytoma and Paraganglioma
2006 StandoutNobel
Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein
2000
von Hippel-Lindau Protein Induces Hypoxia-regulated Arrest of Tyrosine Hydroxylase Transcript Elongation in Pheochromocytoma Cells
1999
The fission yeast COP9/signalosome is involved in cullin modification by ubiquitin-related Ned8p
2001
The von Hippel–Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis
2004
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Choosing anticancer drug targets in the postgenomic era
1999 StandoutNobel
The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIMEL
2009
Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast
2000
Identification of NEDD8-Conjugation Site in Human Cullin-2
1999
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL -mutant renal carcinoma cells
2008
von Hippel‐Lindau tumor suppressor protein represses platelet‐derived growth factor B‐chain gene expression via the Sp1 binding element in the proximal PDGF‐B promoter
2002
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
1998 StandoutNatureNobel
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Renal-Cell Carcinoma
1996 Standout
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
2006
The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity
2012 StandoutNobel
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
2000
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
2001
The von Hippel–Lindau tumor suppressor protein
2001 StandoutNobel
The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases
2000
Links between metabolism and cancer
2012
Molecular Genetic Analysis of the von Hippel-Lindau Disease Tumor Suppressor Gene in Familial and Sporadic Cerebellar Hemangioblastomas
1997
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Inhibition of SIRT1 Impairs the Accumulation and Transcriptional Activity of HIF-1α Protein under Hypoxic Conditions
2012
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma
2007
Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis
1998
von Hippel-Lindau Disease
1997 StandoutNobel
Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2
2007
The biology of VEGF and its receptors
2003 Standout
The von Hippel–Lindau tumour suppressor interacts with microtubules through kinesin‐2
2007
From Sirtuin Biology to Human Diseases: An Update
2012
The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis
2000
von Hippel–Lindau tumor suppressor: not only HIF's executioner
2004
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
Proteolysis and the cell cycle: with this RING I do thee destroy
2000
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
1995 Science
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
2000 StandoutNobel
Germline and Somatic Mutations in von Hippel-Lindau Disease Gene and Its Significance in the Development of Kidney Cancer
1999
Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas Is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α
1998
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
How oxygen makes its presence felt: Figure 1.
2002 StandoutNobel
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
2002 StandoutNobel
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1α ubiquitination and degradation
2007 StandoutNobel
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 α-Subunit (HIF-1α)
1998 StandoutNobel
Regulation of Transcription by Ubiquitination without Proteolysis
2000
Siah2 Regulates Stability of Prolyl-Hydroxylases, Controls HIF1α Abundance, and Modulates Physiological Responses to Hypoxia
2004
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
2003 StandoutNobel
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
1998 StandoutNobel
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C
2001
The Elongin B Ubiquitin Homology Domain
1999
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
2003 StandoutNobel
Themes and variations on ubiquitylation
2001
An intact HDM2 RING-finger domain is required for nuclear exclusion of p53
2000
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
2006 StandoutNobel
Molecular and biological properties of vascular endothelial growth factor
1999
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
1997
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
2001
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
1999
The Nedd8-conjugated ROC1-CUL1 Core Ubiquitin Ligase Utilizes Nedd8 Charged Surface Residues for Efficient Polyubiquitin Chain Assembly Catalyzed by Cdc34
2002
VEGF and the quest for tumour angiogenesis factors
2002
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
2002
MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300
2003
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
2003 Standout
Mechanisms of angiogenesis
1997 StandoutNature
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
2005
VHL, the story of a tumour suppressor gene
2014
The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain
1999
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 in normoxia
2003 Standout
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
2013 Standout
HIF-2α downregulation in the absence of functional VHL is not sufficient for renal cell differentiation
2007
Genetic Analysis of Pathways Regulated by the von Hippel-Lindau Tumor Suppressor in Caenorhabditis elegans
2004 StandoutNobel
Formation of the VHL–Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC
1999
Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma
2005
Ubiquitin-like proteins: new wines in new bottles
2000
Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor
2001 StandoutNobel
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
1998
aHIF: a Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia
1999
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein
2006
Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR
1998
The Hallmarks of Aging
2013 Standout
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
Regulation of the Erythropoietin Gene
1989
Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1
1999 StandoutNobel
Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
2002
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
2013
SGT1 Encodes an Essential Component of the Yeast Kinetochore Assembly Pathway and a Novel Subunit of the SCF Ubiquitin Ligase Complex
1999
Identification of Elongin C Sequences Required for Interaction with the von Hippel-Lindau Tumor Suppressor Protein
1997
Cancer-related inflammation
2008 StandoutNature
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
1997
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
2003 Nature
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
2003
Modes of resistance to anti-angiogenic therapy
2008 Standout
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
2016 StandoutNobel
Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1α
2010
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
1996
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
1999
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
2000 StandoutNobel
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells
2013
Selective Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl-Hydroxylase 1 Mediates Neuroprotection against Normoxic Oxidative Death via HIF- and CREB-Independent Pathways
2009 StandoutNobel
Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia
2002
Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ
1998
HIF activation identifies early lesions in VHL kidneys
2002 StandoutNobel
Modes of regulation of ubiquitin-mediated protein degradation
2000 StandoutNobel
Multiple Splice Variants of the Human HIF-3α Locus Are Targets of the von Hippel-Lindau E3 Ubiquitin Ligase Complex
2003
Software and database for the analysis of mutations in the VHL gene
1998
Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells
2012
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
1999
Metabolic switching and fuel choice during T‐cell differentiation and memory development
2012
Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesis
1998
pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition
2006
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
1999
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
1996
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
2000 StandoutNobel
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
The von Hippel–Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells
2006
Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation
2011 Standout
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
1996
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
2000
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein
1998
Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells
1999
Role of transforming growth factor-α in von Hippel– Lindau\n (VHL)−/− clear cell renal carcinoma cell proliferation: A\n possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
1997
von Hippel-Lindau Disease
2006 StandoutNobel
Elongin (SIII): A Multisubunit Regulator of Elongation by RNA Polymerase II
1995 Science
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
A Nedd8 conjugation pathway is essential for proteolytic targeting of p27 Kip1 by ubiquitination
2000
Coordinate Regulation of the Oxygen-Dependent Degradation Domains of Hypoxia-Inducible Factor 1α
2005
SCF and Cullin/RING H2-Based Ubiquitin Ligases
1999
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
1997
PROLINE HYDROXYLATION AND GENE EXPRESSION
2005 StandoutNobel
The Biology of Vascular Endothelial Growth Factor
1997 Standout
Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
1996
The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
1996
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Carboxyl-Terminal Transactivation Activity of Hypoxia-Inducible Factor 1α Is Governed by a von Hippel-Lindau Protein-Independent, Hydroxylation-Regulated Association with p300/CBP
2002
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
2003
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Primary Cilium Formation Requires von Hippel-Lindau Gene Function in Renal-Derived Cells
2006
The APC11 RING-H2 Finger Mediates E2-Dependent Ubiquitination
2000
Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor
2006
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis
2015
RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination
1999
Mechanisms Underlying Ubiquitination
2001 Standout
Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein
1999
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
1998
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
2002
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
1997
Hypoxia-Inducible Factor-Dependent Degeneration, Failure, and Malignant Transformation of the Heart in the Absence of the von Hippel-Lindau Protein
2008
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
2005 StandoutNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Phosphorylation- and Skp1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases.
2001
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
1998
Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function
1998
Splicing-Directed Therapy in a New Mouse Model of Human Accelerated Aging
2011
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
1996
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
1998
von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays
2003
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Regulation of the Chemokine Receptor CXCR4 by Hypoxia
2003
pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development
2004 StandoutNobel
NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL
2008
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
2001
Reconstitution of G 1 Cyclin Ubiquitination with Complexes Containing SCF Grr1 and Rbx1
1999 Science
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.
2003 StandoutNobel
Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis
2006
SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production
2013
Regulation of the Erythropoietin Gene
1999
Haemangioblastoma of the central nervous system in von Hippel–Lindau disease
1998
Degradation of the Transcription Factor Gcn4 Requires the Kinase Pho85 and the SCFCDC4Ubiquitin–Ligase Complex
2000
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
2002
The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity
1997
Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
2002
Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
2002
Pathways for Oxygen Regulation and Homeostasis
2016 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
1999 StandoutNobel
von Hippel–Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination
2003
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Phosphorylation Meets Ubiquitination: The Control of NF-κB Activity
2000 Standout
p27 destruction: Cks1 pulls the trigger
2001
Angiogenesis in Endocrine Tumors
2003
Renal Cyst Development in Mice with Conditional Inactivation of the von Hippel-Lindau Tumor Suppressor
2006
Increased Susceptibility to Colitis-Associated Cancer of Mice Lacking TIR8, an Inhibitory Member of the Interleukin-1 Receptor Family
2007
Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.
2001 StandoutNobel
VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling
2001
Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice
2005
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
2001
Vascular endothelial growth factor (VEGF) and its receptors
1999 Standout
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity
2002 StandoutNobel
Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma
2006
Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel–Lindau tumor suppressor function
1999
Works of Othon Iliopoulos being referenced
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
2011 Nature
Small-Molecule Inhibitors of HIF-2a Translation Link Its 5′UTR Iron-Responsive Element to Oxygen Sensing
2008
Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL−/− Tumors
2004
The Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1α
2010
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
1997 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix
1998 StandoutNobel
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
2005
Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene
1997 StandoutNobel
Tumour suppression by the human von Hippel-Lindau gene product
1995 StandoutNobel
Loss of RBF1 changes glutamine catabolism
2013
Genetic and clinical aspects of familial renal neoplasms.
2000
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
1995 StandoutScienceNobel
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer
2004
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
1998 StandoutNobel
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel